SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

Molecular Cancer Therapeutics

Volumn 8, Issue 12, 2009, Pages 3181-3190

  Buchanan, Sean G ^a,e   Hendle, Jorg ^a,e   Lee, Patrick S ^a,e   Smith, Christopher R ^a,e   Bounaud, Pierre Yves ^a   Jessen, Katti A ^a,f   Tang, Crystal M ^a,e   Huser, Nanni H ^a   Felce, Jeremy D ^a   Froning, Karen J ^a   Peterman, Marshall C ^a   Aubol, Brandon E ^a   Gessert, Steve F ^a   Sauder, J Michael ^a,e   Schwinn, Kenneth D ^a,e   Russell, Marijane ^a,e   Rooney, Isabelle A ^a   Adams, Jason ^b   Leon, Barbara C ^a   Do, Tuan H ^a   Blaney, Jeff M ^c   Sprengeler, Paul A ^a,e   Thompson, Devon A ^a,e   Smyth, Lydia ^a   Pelletier, Laura A ^a,e   Atwell, Shane ^a,e   Holme, Kevin ^d   Wasserman, Stephen R ^a,e   Emtage, Spencer ^a,e   Burley, Stephen K ^a,e   Reich, Siegfried H ^a,e   more..

^a SGX Pharmaceuticals Inc   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c GENENTECH INC   (United States)

^d Amira Pharmaceuticals   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f Intellikine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE RON; SCATTER FACTOR RECEPTOR; SGX 523; TYROSINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CATALYSIS; CELL MIGRATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CRYSTALLOGRAPHY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; ENZYME CONFORMATION; ENZYME PHOSPHORYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LUNG CARCINOMA; MOLECULAR STABILITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR XENOGRAFT;

ADENOSINE TRIPHOSPHATE; ANIMALS; CATALYSIS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KINETICS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-MET; PYRIDAZINES; TRIAZOLES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 73149091443     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0477     Document Type: Article

References (37)

1. D'Aniello S, Irimia M, Maeso I, et al. Gene expansion and retention leads to a diverse tyrosine kinase superfamily in amphioxus. Mol Biol Evol 2008;25:1841-54.
2. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
3. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85-94.
4. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. CancerMetastasis Rev 2003;22:309-25.
5. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
6. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16:68-73.
7. Engelman JA, Zejnullahu K, Mitsudomi T, et al. METamplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (New York) 2007;316:1039-43.
8. Koochekpour S, Jeffers M, Rulong S, et al.Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 1997;57:5391-8.
9. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and cmet expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J 2002;16:108-10.
10. Burgess T, Coxon A, Meyer S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006; 66:1721-9.
11. Cao B, Su Y, Oskarsson M, et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc Natl Acad Sci U S A 2001;98:7443-8.
12. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-52.
13. Christensen JG, Schreck R, Burrows J, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003; 63:7345-55.
14. Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.Cancer Res 2007;67:4408-17.
15. Bellon SF, Kaplan-Lefko P, Yang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem 2008;283:2675-83.
16. LoRusso P, Appleman L, Heath E, et al. A phase I study of a novel spectrum selective kinase inhibitor (SSKI), XL880, administered orally in patients with solid tumors. AACR-NCI-EORTC; 2005 Nov 14-18; Pennsylvania Convention Center, Philadelphia, PA; 2005.
17. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995;9:576-96.
18. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-32.
19. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007;408:297-315.
20. Schiering N, Knapp S, Marconi M, et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A 2003;100:12654-9.
21. Collaborative Computational Project Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 1994;50:760-3.
22. Sattler M, Pride YB, Ma P, et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003;63:5462-9.
23. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006;2:358-64.
24. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science (New York) 2002;298:1912-34.
25. Jacobs MD, Caron PR, Hare BJ. Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins 2008;70:1451-60.
26. Park M, Dean M, Cooper CS, et al. Mechanism of met oncogene activation. Cell 1986;45:895-904.
27. Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res 2005;11:2312-9.
28. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999;18:2343-50.
29. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A 1997;94:11445-50.
30. Di Renzo MF, Olivero M, Martone T, et al. Somatic mutations of the METoncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 2000;19:1547-55.
31. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res 2007;67:2081-8.
32. Smolen GA, Sordella R,Muir B, et al. Amplification ofMETmay identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A 2006;103:2316-21.
33. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblastderived modulator of epithelial cell mobility. Nature 1987;327:239-42.
34. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res 2007;67:3529-34.
35. Albrecht BK, Harmange JC, Bauer D, et al. Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinase. J Med Chem 2008;51:2879-82.
36. Perera T, Lavrijssen T, Janssens B, et al. JNJ-38877605: a selective Met kinase inhibitor inducing regression of Met-driven tumor models. 2008.
37. Zou HY, Li Q, Joseph L, et al. PF-04217903, a novel selective c-Met kinase inhibitor with potent antitumor and anti-angiogenic properties in vitro and in vivo. 2008.